Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-cash Items (2019 - 2022)

Historic Non-cash Items for C4 Therapeutics (CCCC) over the last 4 years, with Q1 2022 value amounting to $1.7 million.

  • C4 Therapeutics' Non-cash Items rose 21399.8% to $1.7 million in Q1 2022 from the same period last year, while for Mar 2022 it was $1.7 million, marking a year-over-year increase of 21399.8%. This contributed to the annual value of $1.4 million for FY2021, which is 9867.25% down from last year.
  • C4 Therapeutics' Non-cash Items amounted to $1.7 million in Q1 2022, which was up 21399.8% from $1.4 million recorded in Q4 2021.
  • In the past 5 years, C4 Therapeutics' Non-cash Items registered a high of $102.6 million during Q4 2020, and its lowest value of $531248.0 during Q1 2021.
  • Its 4-year average for Non-cash Items is $15.6 million, with a median of $1.5 million in 2021.
  • As far as peak fluctuations go, C4 Therapeutics' Non-cash Items skyrocketed by 203778.38% in 2020, and later tumbled by 9867.25% in 2021.
  • C4 Therapeutics' Non-cash Items (Quarter) stood at $4.8 million in 2019, then soared by 2037.78% to $102.6 million in 2020, then plummeted by 98.67% to $1.4 million in 2021, then rose by 22.43% to $1.7 million in 2022.
  • Its Non-cash Items was $1.7 million in Q1 2022, compared to $1.4 million in Q4 2021 and $1.1 million in Q3 2021.